PET Imaging in the Evaluation of Cancer Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nuclear Medicine & Radiology".

Deadline for manuscript submissions: closed (25 March 2024) | Viewed by 2282

Special Issue Editors

Department of Nuclear Medicine PET/CT Centre, S. Maria della Misericordia Hospital, 45100 Rovigo, Italy
Interests: molecular imaging; PET; breast cancer; prostate cancer; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Nuclear Medicine Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy
Interests: PET/CT; nuclear medicine; neuro-oncology; lung cancer; prostate cancer; lymphoma; immunotherapy; radiomics; radioembolization

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit your manuscript to this Special Issue entitled “PET imaging in the Evaluation of Cancer Treatment”. PET/CT and/or PET/MRI provide a hybrid functional and morphological imaging, which is particularly useful to guide clinicians for treatment selection, to evaluate the response to oncological treatments, and to assess recurrence and clinical outcomes. Despite several response criteria having been proposed (i.e., EORTC and PERCIST criteria), they are not always used in clinical practice and are unable to correctly assess the response to treatment in 100% of cases. Other parameters, such as volumetric ones, are often published in research papers but are not currently included in any response criteria.

This call is open to all papers investigating PET imaging in cancer treatment assessment. We will evaluate papers discussing the role of PET imaging in the selection and eligibility of patients for a determined cancer treatment. Moreover, papers discussing the therapy response based on PET/CT findings, whether with the use of recognised response criteria, visual assessment, semiquantitative parameters, or radiomics and artificial intelligence, will be considered. Finally, we will also consider papers discussing the role of PET imaging in follow-up, both for recurrence assessment and for the evaluation of patients’ outcomes.

We aim at publishing high-quality original articles, reviews, and metanalysis able to have a significant impact on clinical practice.

Dr. Luca Urso
Dr. Angelo Castello
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PET/CT or PET/MRI
  • treatment selection
  • therapy response assessment
  • response criteria
  • semi-quantitative parameters
  • radiomics features
  • artificial intelligence
  • targeted therapy
  • recurrence
  • survival

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 1560 KiB  
Article
Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors
by Kalevi Kairemo, Mohamed Gouda, Hubert H. Chuang, Homer A. Macapinlac and Vivek Subbiah
J. Clin. Med. 2024, 13(11), 3269; https://doi.org/10.3390/jcm13113269 - 31 May 2024
Viewed by 359
Abstract
Background/Objectives: The inhibitory effects of tyrosine kinase inhibitors (TKIs) on glucose uptake through their binding to human glucose transporter-1 (GLUT-1) have been well documented. Thus, our research aimed to explore the potential impact of various TKIs of GLUT-1 on the standard [ [...] Read more.
Background/Objectives: The inhibitory effects of tyrosine kinase inhibitors (TKIs) on glucose uptake through their binding to human glucose transporter-1 (GLUT-1) have been well documented. Thus, our research aimed to explore the potential impact of various TKIs of GLUT-1 on the standard [18F]FDG-PET monitoring of tumor response in patients. Methods: To achieve this, we conducted an analysis on three patients who were undergoing treatment with different TKIs and harbored actionable alterations. Alongside the assessment of FDG data (including SUVmax, total lesion glycolysis (TLG), and metabolic tumor volume (MTV)), we also examined the changes in tumor sizes through follow-up [18F]FDG-PET/CT imaging. Notably, our patients harbored alterations in BRAFV600, RET, and c-KIT and exhibited positive responses to the targeted treatment. Results: Our analysis revealed that FDG data derived from SUVmax, TLG, and MTV offered quantifiable outcomes that were consistent with the measurements of tumor size. Conclusions: These findings lend support to the notion that the inhibition of GLUT-1, as a consequence of treatment efficacy, could be indirectly gauged through [18F] FDG-PET/CT imaging in cancer patients undergoing TKI therapy. Full article
(This article belongs to the Special Issue PET Imaging in the Evaluation of Cancer Treatment)
Show Figures

Figure 1

Review

Jump to: Research

14 pages, 1431 KiB  
Review
PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
by Luca Urso, Luca Filippi, Angelo Castello, Maria Cristina Marzola, Mirco Bartolomei, Corrado Cittanti, Luigia Florimonte, Massimo Castellani, Paolo Zucali, Alessio Bruni, Roberto Sabbatini, Massimo Dominici, Stefano Panareo and Laura Evangelista
J. Clin. Med. 2023, 12(22), 7130; https://doi.org/10.3390/jcm12227130 - 16 Nov 2023
Cited by 3 | Viewed by 1535
Abstract
Background: prostate-specific membrane antigen (PSMA) ligand PET has been recently incorporated into international guidelines for several different indications in prostate cancer (PCa) patients. However, there are still some open questions regarding the role of PSMA ligand PET in castration-resistant prostate cancer (CRPC). The [...] Read more.
Background: prostate-specific membrane antigen (PSMA) ligand PET has been recently incorporated into international guidelines for several different indications in prostate cancer (PCa) patients. However, there are still some open questions regarding the role of PSMA ligand PET in castration-resistant prostate cancer (CRPC). The aim of this work is to assess the clinical value of PSMA ligand PET/CT in patients with CRPC. Results: PSMA ligand PET has demonstrated higher detection rates in comparison to conventional imaging and allows for a significant reduction in the number of M0 CRPC patients. However, its real impact on patients’ prognosis is still an open question. Moreover, in CRPC patients, PSMA ligand PET presents some sensitivity and specificity limitations. Due to its heterogeneity, CRPC may present a mosaic of neoplastic clones, some of which could be PSMA−/FDG+, or vice versa. Likewise, unspecific bone uptake (UBU) and second primary neoplasms (SNPs) overexpressing PSMA in the neoangiogenic vessels represent potential specificity issues. Integrated multi-tracer imaging (PSMA ligand and [18F]FDG PET) together with a multidisciplinary discussion could allow for reaching the most accurate evaluation of each patient from a precision medicine point of view. Full article
(This article belongs to the Special Issue PET Imaging in the Evaluation of Cancer Treatment)
Show Figures

Figure 1

Back to TopTop